Compare OSK & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSK | SYRE |
|---|---|---|
| Founded | 1917 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 8.5B |
| IPO Year | 2009 | 2015 |
| Metric | OSK | SYRE |
|---|---|---|
| Price | $157.91 | $93.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $166.79 | $85.08 |
| AVG Volume (30 Days) | 734.0K | ★ 795.7K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $7,705,500,000.00 | N/A |
| Revenue This Year | $5.94 | N/A |
| Revenue Next Year | $7.19 | N/A |
| P/E Ratio | $136.17 | ★ N/A |
| Revenue Growth | ★ 12.83 | N/A |
| 52 Week Low | $116.77 | $14.51 |
| 52 Week High | $180.49 | $110.18 |
| Indicator | OSK | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 58.79 | 38.06 |
| Support Level | $138.41 | $66.78 |
| Resistance Level | $158.91 | $106.10 |
| Average True Range (ATR) | 4.41 | 4.57 |
| MACD | 0.10 | -1.11 |
| Stochastic Oscillator | 82.40 | 12.26 |
Oshkosh is a leading maker of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, including postal, firefighting, refuse/recycling collection, aviation, and construction. It is typically the market share leader or No. 2 player in North America, or even the global leader in the case of its JLG aerial work platform business. The transport segment is a leading provider of light trucks to the military and vehicles to the Postal Service. The vocational segment, featuring brands such as Pierce, AeroTech, and Volterra, offers purpose-built vehicles and equipment to municipalities. The company reports three segments—Access equipment (45% of revenue), Vocational (35%), and Transport (20%) on 2025 revenue of $10.4 billion.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.